Please note that UPSpace will be unavailable from Friday, 2 May at 18:00 (South African Time) until Sunday, 4 May at 20:00 due to scheduled system upgrades. We apologise for any inconvenience this may cause and appreciate your understanding.
dc.contributor.author | Pretorius, Etheresia![]() |
|
dc.contributor.author | Swanepoel, A.C. (Albe Carina)![]() |
|
dc.contributor.author | Buys, A.V. (Antonia Vergina)![]() |
|
dc.contributor.author | Vermeulen, Natasha![]() |
|
dc.contributor.author | Duim, Wiebren![]() |
|
dc.contributor.author | Kell, Douglas B.![]() |
|
dc.date.accessioned | 2015-05-14T06:10:13Z | |
dc.date.available | 2015-05-14T06:10:13Z | |
dc.date.issued | 2014-10 | |
dc.description.abstract | A major trend in recent Parkinson’s disease (PD) research is the investigation of biological markers that could help in identifying at‐risk individuals or to track disease progression and response to therapies. Central to this is the knowledge that inflammation is a known hallmark of PD and of many other degenerative diseases. In the current work, we focus on inflammatory signalling in PD, using a systems approach that allows us to look at the disease in a more holistic way. We discuss cyclooxygenases, prostaglandins, thromboxanes and also iron in PD. These particular signalling molecules are involved in PD pathophysiology, but are also very important in an aberrant coagulation/hematology system. We present and discuss a hypothesis regarding the possible interaction of these aberrant signalling molecules implicated in PD, and suggest that these molecules may affect the erythrocytes of PD patients. This would be observable as changes in the morphology of the RBCs and of PD patients relative to healthy controls. We then show that the RBCs of PD patients are indeed rather dramatically deranged in their morphology, exhibiting eryptosis (a kind of programmed cell death). This morphological indicator may have useful diagnostic and prognostic significance. | en_ZA |
dc.description.librarian | am2015 | en_ZA |
dc.description.sponsorship | Biotechnology and Biological Sciences Research Council (grant BB/L025752/1) and the National Research Foundation (NRF) of South Africa. | en_ZA |
dc.description.uri | http://www.impactaging.com/index.html | en_ZA |
dc.identifier.citation | Pretorius, E, Sawnepoel, AC, Buys, AV, Vermeulen, N, Duim, W & Kell, DB 2014, 'Eryptosis as a marker of Parkinson’s disease', Aging, vol. 6, no. 10, pp. 788-819. | en_ZA |
dc.identifier.issn | 1945-4589 | |
dc.identifier.uri | http://hdl.handle.net/2263/45151 | |
dc.language.iso | en | en_ZA |
dc.publisher | Impact Journals | en_ZA |
dc.rights | Copyright: Pretorius et al. This is an open‐access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. | en_ZA |
dc.subject | Eryptosis | en_ZA |
dc.subject | Parkinson’s disease (PD) | en_ZA |
dc.subject | Hypercoagulability | en_ZA |
dc.subject | Inflammatory signalling | en_ZA |
dc.subject | Erythrocytes (RBCs) | en_ZA |
dc.title | Eryptosis as a marker of Parkinson’s disease | en_ZA |
dc.type | Article | en_ZA |